Literature DB >> 33577782

Oncolytic Viruses for Systemic Administration: Engineering a Whole Different Animal.

Svetlana Atasheva1, Dmitry M Shayakhmetov2.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 33577782      PMCID: PMC7934625          DOI: 10.1016/j.ymthe.2021.02.001

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  15 in total

Review 1.  The importance of natural IgM: scavenger, protector and regulator.

Authors:  Michael R Ehrenstein; Clare A Notley
Journal:  Nat Rev Immunol       Date:  2010-10-15       Impact factor: 53.106

2.  Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.

Authors:  Diane M Roberts; Anjali Nanda; Menzo J E Havenga; Peter Abbink; Diana M Lynch; Bonnie A Ewald; Jinyan Liu; Anna R Thorner; Patricia E Swanson; Darci A Gorgone; Michelle A Lifton; Angelique A C Lemckert; Lennart Holterman; Bing Chen; Athmanundh Dilraj; Angela Carville; Keith G Mansfield; Jaap Goudsmit; Dan H Barouch
Journal:  Nature       Date:  2006-04-16       Impact factor: 49.962

3.  First oncolytic virus approved for melanoma immunotherapy.

Authors:  Jonathan Pol; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-12-08       Impact factor: 8.110

Review 4.  Oncorine, the World First Oncolytic Virus Medicine and its Update in China.

Authors:  Min Liang
Journal:  Curr Cancer Drug Targets       Date:  2018       Impact factor: 3.428

5.  The complement response against an oncolytic virus is species-specific in its activation pathways.

Authors:  Hiroaki Wakimoto; Keiro Ikeda; Tatsuya Abe; Tomotsugu Ichikawa; Fred H Hochberg; R Alan B Ezekowitz; Mark S Pasternack; E Antonio Chiocca
Journal:  Mol Ther       Date:  2002-03       Impact factor: 11.454

6.  Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus.

Authors:  Elena V Shashkova; Konstantin Doronin; Julien S Senac; Michael A Barry
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

7.  Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.

Authors:  Antoni Ribas; Reinhard Dummer; Igor Puzanov; Ari VanderWalde; Robert H I Andtbacka; Olivier Michielin; Anthony J Olszanski; Josep Malvehy; Jonathan Cebon; Eugenio Fernandez; John M Kirkwood; Thomas F Gajewski; Lisa Chen; Kevin S Gorski; Abraham A Anderson; Scott J Diede; Michael E Lassman; Jennifer Gansert; F Stephen Hodi; Georgina V Long
Journal:  Cell       Date:  2017-09-07       Impact factor: 41.582

8.  Vesiculovirus neutralization by natural IgM and complement.

Authors:  Mulu Z Tesfay; Arun Ammayappan; Mark J Federspiel; Glen N Barber; David Stojdl; Kah-Whye Peng; Stephen J Russell
Journal:  J Virol       Date:  2014-03-19       Impact factor: 5.103

Review 9.  Complement and viral pathogenesis.

Authors:  Kristina A Stoermer; Thomas E Morrison
Journal:  Virology       Date:  2011-02-02       Impact factor: 3.616

10.  Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial.

Authors:  Robert H I Andtbacka; Merrick Ross; Igor Puzanov; Mohammed Milhem; Frances Collichio; Keith A Delman; Thomas Amatruda; Jonathan S Zager; Lee Cranmer; Eddy Hsueh; Lisa Chen; Mark Shilkrut; Howard L Kaufman
Journal:  Ann Surg Oncol       Date:  2016-06-24       Impact factor: 5.344

View more
  3 in total

Review 1.  Virotherapy in Germany-Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies.

Authors:  Dirk M Nettelbeck; Mathias F Leber; Jennifer Altomonte; Assia Angelova; Julia Beil; Susanne Berchtold; Maike Delic; Jürgen Eberle; Anja Ehrhardt; Christine E Engeland; Henry Fechner; Karsten Geletneky; Katrin Goepfert; Per Sonne Holm; Stefan Kochanek; Florian Kreppel; Lea Krutzke; Florian Kühnel; Karl Sebastian Lang; Antonio Marchini; Markus Moehler; Michael D Mühlebach; Ulrike Naumann; Roman Nawroth; Jürg Nüesch; Jean Rommelaere; Ulrich M Lauer; Guy Ungerechts
Journal:  Viruses       Date:  2021-07-21       Impact factor: 5.048

Review 2.  Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option.

Authors:  Yi Ren; Jia-Meng Miao; Yuan-Yuan Wang; Zheng Fan; Xian-Bin Kong; Long Yang; Gong Cheng
Journal:  Front Immunol       Date:  2022-07-15       Impact factor: 8.786

Review 3.  Evolving role of seneca valley virus and its biomarker TEM8/ANTXR1 in cancer therapeutics.

Authors:  Virginia Corbett; Paul Hallenbeck; Piotr Rychahou; Aman Chauhan
Journal:  Front Mol Biosci       Date:  2022-08-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.